Gilead Sciences

Director, Risk Based Quality Management

United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

The Director, Risk Based Quality Management should have extensive experience serving as a Lead Subject Matter Expert and Process Owner for assigned areas, processes, and technologies. They must have experience leading collaborations with CRO partners and providing oversight of vendors performing RBQM activities. The role requires participation in audits and regulatory inspections, providing expert guidance, training, and support on RBQM in clinical trials, and advising study teams throughout risk management activities. Experience contributing to the development of new central monitoring tools and identifying/defining Quality Tolerance Limits, risks, thresholds, mitigations, and performance indicators is necessary. The candidate must also have experience in developing, enhancing, and implementing RBQM processes, systems, templates, tools, and training materials, managing RACT libraries, and leading or contributing to cross-functional committees, projects, and workstreams. Experience developing and analyzing RBQM performance metrics and serving as a champion for change initiatives is also required. Strong partnership-building skills with service providers and the ability to influence strategic relationships are essential.

Responsibilities

The Director, Risk Based Quality Management will serve as a Lead Subject Matter Expert and Process Owner for assigned areas, processes, and technologies. They will lead collaborations with CRO partners and provide oversight of vendors performing RBQM activities, ensuring alignment with Gilead’s RBQM framework. This role involves supporting inspection-readiness, participating in audits and regulatory inspections, and providing expert guidance, training, and support on RBQM in clinical trials. The Director will advise study teams on risk management, contribute to the development of central monitoring tools, and participate in determining monitoring strategies and mitigation plans. They will also facilitate cross-functional risk review meetings, oversee the timely resolution of risk signals, and lead the development, enhancement, and implementation of RBQM processes, systems, templates, tools, and training materials. Managing RACT libraries, leading or contributing to continuous improvement initiatives, developing and analyzing RBQM performance metrics, and championing change initiatives are also key responsibilities. Additionally, the Director will build and maintain strong partnerships with service providers and represent Gilead in industry-wide collaborations.

Skills

Risk Based Quality Management (RBQM)
Clinical Trials
Vendor Oversight
Audit Support
Regulatory Inspections
Process Improvement
Subject Matter Expertise

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters
1987Year Founded
$15,873.6MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.
Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.
Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.
Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.
Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.
Investment in digital health technologies enhances Gilead's R&D and patient engagement.
Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI